Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Harvard Bioscience, Inc. (NASDAQ: HBIO).

Full DD Report for HBIO

You must become a subscriber to view this report.


Recent News from (NASDAQ: HBIO)

Harvard Bioscience Presents Data, Symposium Session and New Products at Neuroscience 2018
HOLLISTON, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, is presenting its new neuroscience products and applications for preclinical life science researc...
Source: GlobeNewswire
Date: November, 02 2018 14:30
Harvard Bioscience: Long-Term Growth, Margin Improvements Equals Strong Stock Appreciation
Harvard Bioscience ( HBIO ) has multiple things going for them to catalyze the stock for above average gains over the next year. The completion of the Data Sciences International [DSI] acquisition in January 2018 has led to significant top line and bottom line growth. The focus on cost cutti...
Source: SeekingAlpha
Date: October, 29 2018 14:36
Harvard Bioscience EPS in-line, misses on revenue
Harvard Bioscience (NASDAQ: HBIO ): Q3 Non-GAAP EPS of $0.04 in-line; GAAP EPS of -$0.01 beats by $0.01 . More news on: Harvard Bioscience, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: October, 25 2018 16:04
Harvard Bioscience Reports Third Quarter 2018 Financial Results
-Reports GAAP and adjusted non-GAAP revenue of $28.6 million and $28.7 million, respectively, an increase of 53% and 15%, respectively- HOLLISTON, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”), a global developer...
Source: GlobeNewswire
Date: October, 25 2018 16:02
Harvard Bioscience names Kam Unninayar as CFO
Harvard Bioscience (NASDAQ: HBIO ) announces the appointment of Kam Unninayar as Chief Financial Officer, effective November 26, 2018. Ms. Unninayar succeeds Robert E. Gagnon, who resigned. More news on: Harvard Bioscience, Inc., Read more ...
Source: SeekingAlpha
Date: October, 22 2018 17:58
Harvard Bioscience Names Kam Unninayar as Chief Financial Officer
Seasoned Financial Executive With More Than a Decade in Global Life Science Instrumentation, Will Begin on November 26 HOLLISTON, Mass., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”), a global developer, manufacturer and ma...
Source: GlobeNewswire
Date: October, 22 2018 16:11
Harvard Bioscience Schedules Third Quarter 2018 Conference Call for October 25 at 4:30 PM ET
HOLLISTON, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its third quarter 2018 after market trading hours on Thursday, October ...
Source: GlobeNewswire
Date: October, 18 2018 16:30
Harvard Bioscience Announces Management Change
HOLLISTON, Mass., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, today announced the resignation of Robert E. Gagnon, Chief Financia...
Source: GlobeNewswire
Date: August, 22 2018 08:30
Week 34 Breakout Forecast: Short-Term Picks To Give You An Edge
Breakout Forecast Selections for Week 34: Market conditions continue with low positive breakout momentum and increasing negative momentum. The positive momentum gauge has continued to decline into the red to 19 down from a value of 37 at the end of the prior week. The red positive momentum...
Source: SeekingAlpha
Date: August, 20 2018 06:12
Week 31 Breakout Forecast: Short-Term Picks To Give You An Edge
Breakout Forecast Selections for Week 31: Market conditions continue with low breakout momentum and worsening negative momentum. The positive momentum gauge continues to decline into the red at 23 down from a value of 27 at the end of the prior week. These low momentum conditions signal...
Source: SeekingAlpha
Date: July, 28 2018 18:51

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-143.393.253.513.2450,346
2018-12-133.473.433.523.3141,628
2018-12-123.483.4653.583.4126,694
2018-12-113.523.483.593.4424,368
2018-12-103.503.433.56253.3826,446

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-147,08918,02039.3396Short
2018-12-137,10616,41743.2844Short
2018-12-125,2119,68353.8160Short
2018-12-112,60213,47319.3127Cover
2018-12-104,40912,26035.9625Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on HBIO.


About Harvard Bioscience, Inc. (NASDAQ: HBIO)

Logo for Harvard Bioscience, Inc. (NASDAQ: HBIO)

Not available

 

Contact Information

 

 

Current Management

  • Chane Graziano / CEO
  • David Green / President
  • Mark Norige / COO
  • Tom McNaughton / CFO
  • James Warren / CFO

Current Share Structure

  • Market Cap: $174,414,530 - 05/11/2018
  • Issue and Outstanding: 35,594,802 - 03/09/2018

 


Recent Filings from (NASDAQ: HBIO)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: April, 30 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: April, 17 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 06 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 06 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 02 2018
Amendment to a previously filed 8-A12B
Filing Type: 8-A12B/AFiling Source: edgar
Filing Date: March, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 01 2018

 

 


Daily Technical Chart for (NASDAQ: HBIO)

Daily Technical Chart for (NASDAQ: HBIO)


Stay tuned for daily updates and more on (NASDAQ: HBIO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: HBIO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in HBIO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of HBIO and does not buy, sell, or trade any shares of HBIO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/